Smell dysfunction: a biomarker for COVID‐19

Shima T. Moein,Seyed MohammadReza Hashemian,Babak Mansourafshar,Ali Khorram‐Tousi,Payam Tabarsi,Richard L. Doty
DOI: https://doi.org/10.1002/alr.22587
2020-06-18
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>SARS‐CoV‐2, the virus that causes COVID‐19 disease, is responsible for the largest pandemic since the 1918 H1N1 influenza outbreak. The symptoms presently recognized by the World Health Organization are cough, fever, tiredness, and difficulty breathing. Patient‐reported smell and taste loss has been associated with COVID‐19 infection, yet no empirical olfactory testing on a cohort of COVID‐19 patients has been performed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The University of Pennsylvania Smell Identification Test (UPSIT), a well‐validated 40‐odorant test, was administered to 60 confirmed COVID‐19 inpatients and 60 age‐ and sex‐matched controls to assess the magnitude and frequency of their olfactory dysfunction. A mixed effects analysis of variance determined whether meaningful differences in test scores existed between the two groups and if the test scores were differentially influenced by sex.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Fifty‐nine (98%) of the 60 patients exhibited some smell dysfunction [mean (95% CI) UPSIT score: 20.98 (19.47,22.48); controls: 34.10 (33.31,34.88); p&lt;0.0001]. Thirty‐five of the 60 patients (58%) were either anosmic (15/60; 25%) or severely microsmic (20/60; 33%); 16 exhibited moderate microsmia (16/60; 27%), 8 mild microsmia (8/60; 13%), and one normosmia (1/60; 2%). Deficits were evident for all 40 UPSIT odorants. No meaningful relationships between the test scores and sex, disease severity, or comorbidities were found.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Quantitative smell testing demonstrates that decreased smell function, but not always anosmia, is a major marker for SARS‐CoV‐2 infection and suggests the possibility that smell testing may help, in some cases, to identify COVID‐19 patients in need of early treatment or quarantine.</p><p>This article is protected by copyright. All rights reserved</p></section>
otorhinolaryngology
What problem does this paper attempt to address?